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Abstract
Patients with pneumonia treated in the internal medicine department (IMD) are often at risk of healthcare-associated pneumonia
(HCAP). The importance of HCAP is controversial. We invited physicians from 72 IMDs to report on all patients with pneumonia hos-
pitalized in their department during 2 weeks (one each in January and June 2010) to compare HCAP with community-acquired pneumo-
nia (CAP) and hospital-acquired pneumonia (HAP). We analysed 1002 episodes of pneumonia: 58.9% were CAP, 30.6% were HCAP
and 10.4% were HAP. A comparison between CAP, HCAP and HAP showed that HCAP patients were older (77, 83 and 80.5 years;
p < 0.001), had poorer functional status (Barthel 100, 30 and 65; p < 0.001) and had more risk factors for aspiration pneumonia (18, 50
and 34%; p < 0.001). The frequency of testing to establish an aetiological diagnosis was lower among HCAP patients (87, 72 and 79;
p < 0.001), as was adherence to the therapeutic recommendations of guidelines (70, 23 and 56%; p < 0.001). In-hospital mortality
increased progressively between CAP, HCAP and HAP (8, 19 and 27%; p < 0.001). Streptococcus pneumoniae was the main pathogen in
CAP and HCAP. Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA) caused 17 and 12.3% of HCAP. In
patients with a confirmed aetiological diagnosis, the independent risk factors for pneumonia due do difficult-to-treat microorganisms
(Enterobacteriaceae, P. aeruginosa or MRSA) were HCAP, chronic obstructive pulmonary diseases and higher Port Severity Index. Our
data confirm the importance of maintaining high awareness of HCAP among patients treated in IMDs, because of the different aetiolo-
gies, therapy requirements and prognosis of this population.
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Introduction
Healthcare-associated pneumonia (HCAP) is an intermediate
category between community-acquired pneumonia (CAP)
and hospital-acquired pneumonia (HAP) [1]. The term was
coined to identify those patients who acquired pneumonia
outside the hospital but were institutionalized or had fre-
quent contact with the healthcare system for the manage-
ment of their chronic underlying diseases [2]. These patients
are at risk for infections caused by nosocomial pathogens
and have a poorer outcome than patients with CAP [3–6]. It
is a matter of debate whether the poorer outcome of HCAP
is related to the higher prevalence of nosocomial pathogens
or to patients’ underlying conditions and whether broad-
spectrum empirical antibiotic therapy is necessary [1,7–9].
The number of hospitalizations for pneumonia has been
increasing in recent years, mainly among elderly patients and
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those with multiple co-morbidities [10,11]. Several studies
show that these patients are frequently managed in the inter-
nal medicine departments (IMDs) [12–19]. Only one study
describes the frequency of HCAP among patients with pneu-
monia treated in the IMDs. The authors compared CAP,
HCAP and HAP and showed that the baseline conditions
and outcome of HCAP patients were more similar to those
of patients with HAP than to those of patients with CAP
[20]. However, no data were provided on the aetiological
pattern of the three groups. Therefore, the question of
whether the outcome of HCAP patients treated in IMDs is
associated only with the underlying conditions or with the
higher frequency of nosocomial pathogens is open to debate.
We performed a large multicentre prospective study to
compare the underlying conditions, aetiological patterns,
therapeutic management and outcome of patients with CAP,
HCAP and HAP treated in the IMDs. We also investigated
the factors associated with poor outcome.
Methods
Study design
We performed a multicentre prospective study in which the
study population was based on a list provided by the Study
Group for Infectious Diseases of the Spanish Society of
Internal Medicine (SEMI). We invited the directors of 412
IMDs in 360 hospitals to participate by mail and email.
Data were collected during two study weeks (one each in
January and June 2010) through a web site (http://ene-
mi2010.com), where the study protocol was available. Access
was restricted to participating members by means of a per-
sonal username and password.
During each study week, the coordinating investigator
contacted the participating members by phone and email to
monitor inclusion of all eligible cases. The completeness and
consistency of the protocols were systematically reviewed
before data were entered into the database. The study was
approved by our local ethics committee.
Patients
We included all adults (>16 years) treated for pneumonia in
the IMD during the study weeks. Pneumonia was defined by
radiological evidence of a new, or progression of a previous,
pulmonary infiltrate plus at least two of the following crite-
ria: fever >38C, cough, purulent sputum, dyspnoea or >20
breaths per minute, pleuritic chest pain, and a leucocyte
count of >10 000/mm3 or <4000/mm3 [20].
Patients were classified as having CAP, HCAP or HAP. All
community-acquired episodes diagnosed within 48 h of
admission in patients who did not fulfill HCAP criteria were
considered CAP. Patients were classified as having HCAP if
they acquired pneumonia outside the hospital but fulfilled
any of the following criteria [2,20]: prior hospitalization
(‡2 days) or surgery in the past 180 days; residence in a
nursing home or long-term care facility; attending hospital
regularly because of chronic underlying diseases; intravenous
therapy, wound care or specialized nursing care at home in
the past 30 days; chemotherapy in the past 30 days; and hae-
modialysis. The criteria for HAP were pneumonia after being
hospitalized for more than 48 h or within 10 days of leaving
the hospital [20]. All patients were questioned about the
presence of any HCAP or HAP criteria at admission.
Measurements
Before enrolling cases in the study, participating centres
were asked to report data collected for the year 2009,
including number of patients admitted to the IMD, mean days
of stay, and number of patients discharged with a diagnosis
of pneumonia. This was performed to double check the
accuracy of the incidence and other clinical data obtained
during the study weeks. We also collected the number of
admissions to the IMD and that of patients newly diagnosed
with pneumonia.
Demographic data and data on underlying conditions
included age, sex, Charlson co-momorbity index, Barthel
index, and the presence of risk factors for aspiration pneu-
monia such as altered consciousness, altered gag reflex, dys-
phagia, severe periodontal disease or putrid sputum [4].
We recorded the Pneumonia Severity Index (PSI) and the
CURB-65 (confusion, urea nitrogen, respiratory rate, blood
pressure, and age 65 years or older) severity score in CAP
and HCAP patients.
We recorded collection data and results for the follow-
ing samples: blood culture, sputum, bronchial aspirate,
bronchoalveolar lavage, pulmonary biopsy, pneumococcal
and Legionella urinary antigen, serology and nasopharyngeal
swab for detection of the influenza virus. We defined
pneumonia due to difficult-to-treat (DTT) microorganisms
as those episodes caused by Enterobacteriaceae, Pseudomo-
nas aeruginosa or methicillin-resistant Staphylococcus aureus
(MRSA).
Data on therapeutic management included administration
of empirical antibiotic treatment, time from diagnosis to first
antibiotic dose, route of administration, adherence to IDSA
guidelines for the management of CAP [21] and ATS guide-
lines for the management of HAP and HCAP [2]. In patients
with positive cultures, we also evaluated the adequacy of
empirical therapy according to the sensitivity tests of the
causative agent.
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Outcomes were evaluated using the following: time to clini-
cal stability [22]; need for intubation and days of mechanical
ventilation; development of a complication such as empyema,
septic shock and multi-organ failure; persistent bacteraemia
and/or emergence of antibiotic resistance in the causative
organism; in-hospital death; and length of hospitalization from
the diagnosis of pneumonia.
Statistical analysis
Categorical variables are presented as absolute numbers and
their relative frequencies. Quantitative variables are presented
as mean and standard deviation (SD) if normally distributed or
as median and interquartile range (IQR) if non-normally dis-
tributed. We compared categorical variables between three
epidemiological groups (CAP, HCAP and HAP) using the
Pearson chi-squared and Fisher exact tests, while the non-
parametric Mann–Whitney and Kruskal–Wallis tests were
used to compare quantitative variables. A post hoc Bonferroni
correction was performed for pairwise comparisons. Stepwise
logistic regression models were used in the multivariate analy-
sis to analyse risk factors for pneumonia due to DTT micro-
organisms and for in-hospital mortality. Variables with p < 0.1
in the univariate analysis were included in the multivariate
models. Differences were considered to be significant for
p < 0.05. We performed a receiver operating characteristic
(ROC) analysis to determine the sensitivity and specificity of
the model for in-hospital mortality. The analysis was carried
out using SPSS 13.0 (SPSS, Chicago, IL, USA).
Results
Hospital characteristics
The study flow diagram is shown in Fig. 1. Seventy-two IMDs
belonging to 66 Spanish hospitals agreed to participate. Of
these, 47% were teaching institutions and 94% public institu-
tions, with only one private facility and three mixed (public-
private) centres. The overall catchment population was
16 041 888 inhabitants (range, 35 868–1 100 000 inhabitants
per hospital). The total number of beds in the institutions
was 28 896 (range, 82–1559 beds).
Incidence of pneumonia
A retrospective survey of the year 2009 showed an inci-
dence of pneumonia in IMDs of 117 episodes per 1000
admissions. The incidence of pneumonia during the study
weeks was 111 episodes per 1000 admissions, ranging from
141 episodes per 1000 admissions in the first week (January
2010) to 75.3 episodes per 1000 admissions in the second
week (June 2010).
Comparison between CAP, HCAP and HAP
Community-acquired pneumonia was diagnosed in 58.9% of
patients, HCAP in 30.6%, and HAP in 10.5%. The most com-
mon inclusion criteria for HCAP patients are shown in Table 1.
Table 2 shows the comparison of the three pneumonia
groups. HCAP patients were older and had more co-morbid-
ities than CAP patients. They also had a poorer functional
status and more frequent cerebrovascular disease, dementia
and risk factors for aspiration pneumonia than HAP patients.
Cough and pleuritic chest pain were more common among
patients with CAP, while dyspnoea and altered mental status
Potential eligible patients (n = 1043) 
Patients enrolled (n = 1031) 
Patients with no data available
(n = 12) 
Patients who did not fulfil the
criteria for pneumonia (n = 29)  
Patients analyzed (n = 1002) 
First study week 
(January 2010) 
(n = 685)
Second study week
(June 2010)
(n = 317) 
Incident cases*
(n = 612) 
Incident cases*
(n = 276)
412 IMDs belonging to 360 hospitals were invited to participate 
72 IMDs belonging to 66 hospitals agreed to participate 
FIG. 1. Study flow diagram. *Incident cases refer to patients newly
diagnosed with pneumonia during the study weeks.
TABLE 1. Inclusion criteria for the HCAP group
n = 307 (%)a
Hospitalization in the past 180 days 170 (55.4)
Residence in a nursing home or long-term care facility 169 (55)
Attending hospital regularly because of chronic underlying diseases 169 (55)
Wound care or specialized nursing care in the past 30 days 49 (16)
Intravenous therapy at home in the past 30 days 38 (12.4)
Surgery in the past 180 days 19 (6.2)
Chemotherapy in the past 30 days 11 (3.6)
Undergoing haemodialysis 0
HCAP, healthcare-associated pneumonia.
aThe numbers and percentages add up to more than the total, as many patients
presented more than one HCAP criterion.
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were seen more frequently among HCAP and HAP patients.
In CAP patients, adherence to IDSA guidelines on empirical
antibiotic treatment was 69.9%, while in HCAP and HAP
patients adherence to ATS guidelines was 22.8 and 55.8%,
respectively (p < 0.001). Among patients with positive cul-
tures, the adequacy of empirical therapy according to sensi-
tivity tests was lower in HCAP cases, but differences were
not significant. Complications such as septic shock,
multi-organ failure, persistent bacteraemia and emergence of
multidrug resistance in the causative pathogens were more
common among HCAP and HAP patients than among CAP
patients. In CAP, HCAP and HAP, the median length of stay
(IQR) after diagnosis was, respectively, 8 (5–13), 9 (6–14)
and 11 (6–16) days (p = 0.002), and in-hospital mortality was
7.8, 18.9 and 26.9% (p < 0.001).
The median PSI and CURB-65 scores of HCAP patients
were higher than those of CAP patients (Table 3).
Use of microbiological resources
An aetiological diagnosis (one or more samples sent to the
microbiology laboratory) was attempted in 86.8, 72 and
78.8% of CAP, HCAP and HAP patients, respectively
(p < 0.001). Overall, 34.4% of patients were already on anti-
microbial therapy at the time of sample collection.
TABLE 2. Comparison of underly-
ing conditions, clinical manifesta-
tions, therapeutic management
and outcome of patients cared for
in internal medicine departments
CAP, n = 591 (%) HCAP, n = 307 (%) HAP, n = 104 (%) p
Demographic data
Age, years (median, IQR) 77, 65–84 83, 76–89 80.5, 73–85.7 <0.001a,b
Male sex 371 (62.8) 177 (57.7) 68 (65.4) 0.22
Co-morbid conditions
COPD 221 (37.4) 125 (40.7) 49 (47) 0.15
Congestive heart failure 126 (21.3) 88 (28.7) 38 (36.5) 0.001b
Diabetes mellitus 149 (25.2) 94 (30.6) 33 (31.7) 0.13
Cerebrovascular disease 106 (17.9) 115 (37.5) 24 (23) <0.001a,c
Dementia 98 (16.6) 150 (48.9) 28 (26.9) <0.001a,c
Cancer 77 (13) 69 (22.5) 27 (26) <0.001a,b
Chronic renal failure 78 (13.2) 66 (21.5) 20 (19.2) 0.004a
Chronic liver failure 49 (8.3) 30 (9.8) 13 (12.5) 0.35
Autoimmune diseases 21 (3.6) 15 (4.9) 5 (4.8) 0.57
HIV infection 22 (3.7) 4 (1.3) 4 (3.8) 0.09
Charlson score (median, IQR) 5, 4–7 7, 6–10 7, 5–10 <0.001a,b
Barthel index (median, IQR) 100, 60–100 30, 0–80 65, 20–100 <0.001a,b,c
RF for aspiration pneumonia 108 (18.3) 154 (50.2) 35 (33.7) <0.001a,b,c
Manifestations of pneumonia
Fever 349 (59) 157 (51) 66 (63.5) 0.03
Cough 480 (81.2) 222 (72.3) 67 (64.4) <0.001a,b
Purulent sputum 342 (57.9) 150 (48.9) 54 (51.9) 0.03
Dyspnoea 438 (74) 253 (82.4) 92 (88.5) <0.001a,b
Pleuritic chest pain 158 (26.7) 33 (10.7) 13 (12.5) <0.001a,b
Altered mental status 115 (19.5) 142 (46.3) 45 (43.3) <0.001a,b
Leukocytosis 434 (73.4) 199 (64.8) 73 (70.2) 0.03a
Leukopenia 24 (4.1) 16 (5.2) 5 (4.8) 0.73
Multilobar infiltrates 150 (25.4) 85 (27.7) 39 (37.5) 0.04
Cavitation 7 (1.2) 5 (1.6) 0 0.46
Interstitial infiltrate 62 (10.5) 39 (12.7) 10 (9.6) 0.55
Pleural effusion 120 (20.3) 54 (17.6) 27 (26) 0.17
Therapeutic management
Empirical therapy 588 (99.5) 302 (98.4) 102 (98) 0.10
Administration within 6 h 420 (71) 211 (68.7) 74 (71.2) 0.79
Adherence to guidelinesd 413 (69.9) 70 (22.8) 58 (55.8) <0.001a,b,c
Adequacy according to sensitivity 54/68 (79.4) 29/45 (64.4) 15/20 (75) 0.27
Days of therapy (median, IQR) 11, 9–14 11, 9–15 12, 9–15 0.79
Outcome
>1 week to clinical stability 89 (15) 75 (24.4) 28 (27) <0.001a,b
Empyema 17 (2.9) 3 (1) 0 0.05
Septic shock 46 (7.8) 45 (14.7) 24 (23.1) 0.001a,b
Need for intubation 20 (3.4) 10 (3.3) 9 (8.7) 0.05
Multi-organ failure 33 (5.6) 34 (11) 21 (20.2) <0.001a,b
Persistent bacteraemia 1 (0.2) 4 (1.3) 2 (1.9) 0.02
Emergence of MDR 4 (0.7) 11 (3.6) 3 (2.9) <0.004a
In-hospital mortality 46 (7.8) 58 (18.9) 28 (26.9) <0.001a,b
Days of hospital staye (median, IQR) 8, 5–13 9, 6–14 11, 6–16 0.002b
CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia; HAP, hospital-acquired pneumonia;
SD, standard deviation; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; RF, risk factors;
MDR, multidrug resistance.
aP < 0.01 for comparison between CAP and HCAP.
bP < 0.01 for comparison between CAP and HAP.
cP < 0.01 for comparison between HCAP and HAP.
dAdherence to guidelines was evaluated according to the IDSA 2007 guidelines for patients with CAP and according
to the ATS 2005 guidelines for those with HCAP and HAP.
eDays of hospital stay were computed from the day pneumonia was diagnosed.
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An aetiological diagnosis was reached in 234 of the 816
patients (28.7%) from whom one or more microbiological
samples were collected. Of these patients, 133 (56.8%) had
positive cultures; in the remaining cases, the diagnosis was
made by urinary antigen tests in 96 (41%), serology in three
(1.3%) and influenza virus test in two (0.8%).
Aetiology
The distribution of causative agents by pneumonia group is
shown in Table 4. Streptococcus pneumoniae was the main
pathogen in CAP and HCAP cases. However, P. aeruginosa
and MRSA were isolated in 17 and 12.3% of HCAP episodes,
respectively. P. aeruginosa and Enterobacteriaceae were the
main pathogens in HAP cases.
For the analysis of the risk factors for pneumonia due to
DTT microorganisms (Table A1 see appendix), patients with
detection of viral pneumonia (3), M. tuberculosis (7), P. jiroveci
(2) and C. burnetii (1) were excluded. Multivariate analysis
showed that history of chronic obstructive pulmonary dis-
ease (COPD) (OR, 2.42; 95% CI, 1.18–4.97; p = 0.02),
HCAP (OR, 3.48; 95% CI, 1.69–7.15; p = 0.001) and higher
PSI (OR, 1.01; 95% CI, 1.00–1.02; p = 0.001) were indepen-
dent risk factors for pneumonia due to DTT microorgan-
isms.
Risk factors for in-hospital mortality
The risk factors for in-hospital mortality according to the
univariate analysis are shown in Table A2 (see Appendix).
Multivariate analysis showed that higher Charlson co-morbid-
ity index, HAP, altered mental status, dyspnoea and multilo-
bar infiltrates were independently associated with in-hospital
mortality, while performance of diagnostic testing was a pro-
tective factor (Table 5). The model had a high predictive
capacity: sensitivity 80% and specificity 77%.
Discussion
We showed that pneumonia generates a considerable
workload for IMDs and that HCAP represents one-third of
cases of pneumonia cared for by internists. HCAP patients
TABLE 3. Comparison of the PSI and CURB-65 scores
Total,
n = 898 (%)
CAP,
n = 591 (%)
HCAP,
n = 307 (%) p
PSI
Median, IQR 123, 92–152 112.5, 83–139 142.5, 116–169 <0.001
Class I or II 104 (11.6) 92 (15.5) 12 (4)
Class III 109 (12) 95 (16) 14 (5)
Class IV 306 (34) 213 (36) 93 (30.3)
Class V 375 (42) 188 (32) 187 (61)
CURB-65
Median, IQR 2, 1–3 2, 1–3 3, 2–3 <0.001
Class 0 100 (11.2) 86 (14.5) 14 (4.6)
Class 1 178 (20.2) 142 (24) 36 (11.8)
Class 2 306 (34.2) 206 (35) 100 (32.5)
Class 3 190 (21.2) 105 (18) 85 (27.5)
Class 4 or 5 120 (13.2) 49 (8) 71 (23.3)
CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia;
PSI, Port severity index; CURB-65, confusion-urea-respiratory rate-blood pres-
sure and age 65 years or older; IQR, interquartile range.
TABLE 4. Distribution of causative agents by pneumonia
group
CAP,
n = 148 (%)
HCAP,
n = 65 (%)
HAP,
n = 21 (%) P
Virus
Influenza A (H1N1)v 2 (1.4) 0 0 1
Gram-positive
S. pneumoniae 94 (63.5) 23 (38.5) 3 (14.3) <0.001a,b
MRSA 1 (0.7) 8 (12.3) 2 (9.5) 0.003a
MSSA 1 (0.7) 1 (1.5) 2 (9.5) 0.03
Gram-negative
Enterobacteriaceae 17 (11.5) 8 (12.3) 5 (23.8) 0.26
P. aeruginosa 5 (3.4) 11 (16.9) 6 (28.6) <0.001a,b
L. pneumophila 11 (7.4) 2 (3.1) 0 0.34
H. influenzae 5 (3.4) 3 (4.6) 0 0.73
A. baumannii 0 0 2 (9.5) 0.008
Other
M. tuberculosis 5 (3.4) 2 (3.1) 0 1
P. jiroveci 1 (0.7) 0 1 (4.8) 0.24
Polymicrobiald 3 (2) 3 (4.6) 0 0.41
Othere 3 (2) 2 (3.1) 0 0.77
Positive culture 68 (45.9) 45 (69.2) 20 (95.2) <0.001a,b
Positive UAT 76 (51.4) 19 (29.2) 1 (4.8) <0.001a,b
CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia;
HAP, hospital-acquired pneumonia; MRSA, methicillin-resistant Staphylococcus
aureus; MSSA, methicillin-sensitive S. aureus; UAT, urinary antigen tests for Legio-
nella and S. pneumoniae.
aP < 0.01 for comparison between CAP and HCAP.
bP < 0.01 for comparison between CAP and HAP.
cP < 0.01 for comparison between HCAP and HAP.
dPolymicrobial included three cases of S. pneumoniae coinfection with influenza
A (H1N1)v virus, MRSA and M. tuberculosis each, two cases of MSSA coinfection
with Enterobacteriaceae, and one case of P. aeruginosa and Nocardia spp. coin-
fection.
eOther included one case of varicella zoster virus infection, one of C. burnetii,
one of C. pneumoniae, one of B. fragilis, and one case of empyema with isolation
of Peptostreptococcus spp. in pleural fluid.
TABLE 5. Multivariate analysis of risk factors for in-hospital
mortality
Adjusted odds
ratio (95% CI) p
Age 1.01 (0.99–1.03) 0.24
Charlson co-morbidity index 1.13 (1.05–1.22) <0.001
Barthel index 0.99 (0.98–1.01) 0.39
Risk factors for aspiration pneumonia 0.87 (0.48–1.57) 0.66
HCAP 1.01 (0.59–1.72) 0.96
HAP 2.27 (1.26–4.10) 0.006
Dyspnoea 2.59 (1.26–5.33) 0.009
Altered mental status 4.24 (2.55–7.04) <0.001
Multilobar infiltrates 2.96 (1.94–4.52) <0.001
Diagnostic testing for aetiological diagnosis 0.59 (0.37–0.94) 0.03
Adherence to guidelines 0.67 (0.42–1.08) 0.10
Receiver operating characteristic (ROC) analysis shows: area under curve
(AUC), 0.86; 95% confidence interval (CI), 0.82–0.89. Sensitivity 80%, specificity
77%.
CI, confidence interval; HCAP, healthcare-associated pneumonia; HAP, hospital-
acquired pneumonia.
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were older and had a poorer functional status than CAP
and HAP patients. The prevalence of difficult-to-treat
microorganisms among HCAP patients was high, and the
infections they caused were frequently inadequately treated
at admission. A progressive increase in poor outcome was
observed between CAP, HCAP and HAP. Higher Charlson
co-morbidity index, severe pneumonia manifestations and
HAP were independently associated with poor outcome,
while performing a microbiological work-up improved sur-
vival.
Pneumonia is an important cause of hospitalization, and
24–75% of patients hospitalized for pneumonia are treated
by internists [12–19,23]. Our incidence of 11.1 episodes per
100 admitted patients represents a high workload and is
almost identical to that obtained by Venditti et al. [20]. In
Spain and Italy, variations between wintertime figures (12,
14%) and summertime figures (5, 7%) are similar.
The type of acquisition should be assessed, because the
importance of HCAP is not well known. One-third of the
patients in our study fulfilled the criteria for HCAP. Our
data confirm the importance of maintaining a high awareness
of HCAP due to the different underlying conditions, therapy
requirements and prognosis of this population [1,3–5,
8,9,20,24,25].
Diagnostic testing is mandatory for CAP patients who
require hospitalization, as it is for those with HCAP or HAP
for epidemiological reasons and because of the risk of multi-
drug-resistant pathogens and the potential for de-escalation
[1,2]. Furthermore, the microbiological study has been asso-
ciated with reduced mortality in patients hospitalized with
CAP [26]. We were able to confirm this finding, as the
microbiological work-up proved to be an independent pro-
tective factor for in-hospital mortality in our study.
The pathogens involved in CAP and HAP in our study
population were as expected and reflect findings reported in
the literature [27–29], with the exception of Enterobacteria-
ceae among CAP patients. COPD, higher median age and
Charlson’s score were associated with Enterobacteriaceae in
our CAP patients (data not shown). The aetiology of HCAP
varies, and some centres find pathogens more similar to
those causing CAP [4,9,30], while others report microorgan-
isms more similar to those causing HAP [3,5,6,31]. In previ-
ous studies the prevalence of multidrug-resistant
microorganisms varied with the study population and was
lower when no immunosuppressed patients attended by
emergency departments were included [4,9,30] and higher if
hospitalized patients with any underlying conditions were
analysed [3,5,6,31]. We were able to confirm this finding.
Despite the fact that S. pneumoniae was the main causative
agent in our HCAP population (38.5%), we found a high pro-
portion of P. aeruginosa, MRSA and Enterobacteriaceae in
that group. Furthermore, HCAP was one of the independent
risk factors for DTT microorganisms (P. aeruginosa, MRSA or
Enterobacteriaceae).
Over the last decade, several national and international
guidelines have been developed to improve the therapeutic
management of pneumonia. In CAP patients, adherence to
empirical therapy guidelines ranged from 33 to 80%
[14,20,32]. The only data available for HCAP are those
reported by Venditti et al. [20], who showed 26.7% adher-
ence to the 2005 ATS guidelines. We confirmed this finding
in our study (23%). These results could indicate low aware-
ness of the potential of DTT microorganisms to cause
HCAP.
Our study is subject to a series of limitations. First, it is
an observational study of two cohorts of patients prospec-
tively included during 1 week each. The small inclusion
period could have affected incidence. However, the choice
of the winter and summer periods minimized this limita-
tion. Indeed the incidence obtained by the retrospective
survey of the year 2009 was similar to that found during
the study period. Second, heterogeneity of the participating
hospitals means that microbiology work-ups and therapeu-
tic management vary. Diagnostic testing (83, 81.5, 73.4%;
p = 0.05), initiation of antibiotics within 6 h (77, 67, 65%;
p = 0.003) and adherence to guidelines (61, 51, 54%;
p = 0.02) were more frequent in hospitals with <500 beds
than in those with 500 to 1000 or >1000 beds, respec-
tively. Finally, the number of patients with a known aetiol-
ogy was low, thus preventing analysis of the impact of
aetiology on outcome.
In conclusion, our data confirm the importance of main-
taining high awareness of HCAP, given the different aetiolo-
gies, therapeutic needs and prognosis of this condition
among patients treated in IMDs.
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Table A1. Risk factors for pneumonia due to difficult-
to-treat (DTT) microorganisms
DDT
microorganisms
n = 68 (%)
Non-DDT
microorganisms
n = 153 (%)
p
Demographic
Age, (median, IQR) (years) 79, 74–86 75, 57–84 <0.001
Male sex 50 (73.5) 89 (58.2) 0.03
Co-morbid conditions
COPD 39 (57.4) 53 (34.6) 0.002
Congestive heart failure 28 (41.2) 27 (17.6) <0.001
Diabetes mellitus 20 (29.4) 30 (19.6) 0.12
Cerebrovascular disease 20 (29.4) 26 (17) 0.05
Cancer 14 (20.6) 18 (11.8) 0.09
Chronic renal failure 14 (20.6) 21 (13.7) 0.23
Chronic liver failure 7 (10.3) 16 (10.5) 1
HIV infection 0 6 (3.9) 0.18
Charlson score (median, IQR) 7, 6–9 5, 3–7 <0.001
Barthel index (median, IQR) 75, 20–100 95, 50–100 0.02
RF for aspiration pneumonia 17 (25) 31 (20.3) 0.48
Pneumonia group
CAP 22 (32.4) 116 (75.8) <0.001
HCAP 31 (45.6) 32 (20.9) <0.001
HAP 15 (22) 5 (3.3) <0.001
Risk stratification of
pneumonia
PSI (median, IQR) 145, 121–167 119, 81–143 <0.001
CURB-65 (median, IQR) 2, 2–4 2, 1–3 0.001
IQR, interquartile range; COPD, chronic obstructive pulmonary dis-
ease; RF, risk factors; CAP, community-acquired pneumonia; HCAP,
healthcare-associated pneumonia; HAP, hospital-acquired pneumonia;
PSI, Port severity index; CURB-65, confusion-urea-respiratory rate-
blood pressure and age 65 years or older.
Table A2. Risk factors for in-hospital mortality
Non-survivors,
n = 132 (%)
Survivors,
n = 870 (%)
p
Demographic
Age, mean (SD) (years) 82.8 (11.3) 74 (16.5) <0.001
Male sex 81 (61.4) 535 (61.5) 1
Co-morbid conditions
COPD 50 (37.9) 345 (39.7) 0.77
Congestive heart failure 36 (26.3) 216 (24.8) 0.6
Diabetes mellitus 15 (11.4) 240 (27.6) 1
Cerebrovascular disease 42 (31.8) 202 (23.2) 0.04
Dementia 69 (52.3) 206 (23.7) <0.001
Cancer 32 (24.2) 141 (16.2) 0.02
Chronic renal failure 36 (26.3) 128 (14.7) 0.001
Chronic liver failure 15 (11.4) 77 (8.9) 0.33
Autoimmune diseases 6 (4.5) 35 (4) 0.81
HIV infection 4 (3) 26 (3) 1
Charlson score (median, IQR) 8, 7–10 6, 4–8 <0.001
Barthel index (median, IQR) 20, 0–65 90, 35–100 <0.001
RF for aspiration pneumonia 75 (56.8) 222 (25.5) <0.001
Pneumonia group
CAP 47 (35.6) 546 (62.8) <0.001
HCAP 53 (43.2) 248 (28.5) 0.001
HAP 28 (21.2) 76 (8.7) <0.001
Pneumonia manifestations and risk stratification
Fever 67 (50.8) 505 (58) 0.13
Cough 95 (72) 674 (77.5) 0.18
Purulent sputum 63 (47.7) 483 (55.5) 0.11
Dyspnoea 122 (92.4) 661 (76) <0.001
Pleuritic chest pain 13 (9.8) 191 (22) 0.001
Altered mental status 93 (70.5) 209 (24) <0.001
Leukocytosis 87 (65.9) 619 (71) 0.22
Leukopenia 8 (6.1) 37 (4.3) 0.36
Multilobar infiltrates 69 (52.3) 205 (23.6) <0.001
Cavitation 2 (1.5) 10 (1.1) 0.66
Interstitial infiltrate 19 (14.4) 92 (10.6) 0.23
Pleural effusion 32 (24.2) 169 (19.4) 0.20
PSI class (median, IQR) IV, IV–IV III, II–IV <0.001
CURB-65 class (median, IQR) 3, 2–4 2, 1–3 <0.001
Severe IDSA/ATS score 99 (75) 249 (28.6) <0.001
Aetiology
Diagnostic testing 86 (65.2) 730 (83.9) <0.001
S. pneumoniae 13/30 (43.3) 109/204 (53.4) 0.33
Enterobacteriaceae 7/30 (23.3) 23/204 (11.3) 0.08
P. aeruginosa 3/30 (10) 19/204 (9.3) 1
L. pneumophila 0 13/204 (6.4) 0.38
MSSA 1/30 (3.3) 3/204 (1.5) 0.42
MRSA 2/30 (6.7) 9/204 (4.4) 0.64
Polymicrobial 2/30 (6.7) 4/204 (2) 0.17
Therapeutic management
Empirical therapy 128 (97) 864 (99.3) 0.03
Administration within 6 h 101 (76.5) 604 (69.4) 0.10
Adherence to guidelinesa 51 (38.6) 492 (56.6) <0.001
Adequacy according to sensitivity 15/21 (71.4) 83/112 (74.1) 0.79
Complications
Empyema 3 (2.3) 17 (2) 0.74
Septic shock 47 (35.6) 27 (3.1) <0.001
Need for intubation 17 (12.9) 22 (2.5) <0.001
Multi-organ failure 73 (55.3) 15 (1.7) <0.001
Persistent bacteraemia 6 (4.5) 1 (0.1) <0.001
Emergence of MDR 6 (4.5) 12 (1.4) 0.06
SD, standard deviation; COPD, chronic obstructive pulmonary dis-
ease; IQR, interquartile range; RF, risk factors; CAP, community-
acquired pneumonia; HCAP, healthcare-associated pneumonia; HAP,
hospital-acquired pneumonia; PSI, Port severity index; CURB-65, confu-
sion-urea-respiratory rate-blood pressure and over 65 years old;
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicil-
lin-sensitive Staphylococcus aureus; MDRmultidrug resistance.
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aAdherence to guidelines was evaluated according to the IDSA 2007
guidelines for patients with CAP and according to the ATS 2005
guidelines for HCAP and HAP patients.
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